TiGenix And Lonza Partner For Complex Perianal Fistulas In Crohn’s Disease Treatment

TiGenix And Lonza Partner For  Complex Perianal Fistulas In Crohn’s Disease Treatment
TiGenix, an advanced biotechnological company committed to developing and marketing new therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) for autoimmune and inflammatory diseases, together with Lonza, a leading and global company of biological and cell therapy manufacturing, have recently announced an agreement for Cx601, TiGenix’s eASC product, to address Crohn’s disease. The new agreement stipulates that Lonza will manufacture material for

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *